



Correction: Share subscriptions based on Nanoform Finland Plc's stock options 1/2020 and 2/2019

Company release

Nanoform Finland Plc

December 18, 2023

16.00 Finnish time / 15.00 Swedish time

Correction: Share subscriptions based on Nanoform Finland Plc's stock options 1/2020 and 2/2019

Correction to the option series in the company release sent on 5 December 2023 at 5:00 pm Finnish time. In the below, release in full with corrected information.

A total of 4,000 Nanoform Finland Plc's (the "**Company**" or "**Nanoform**") new shares has been subscribed for with the Company's stock options **1/2020** and 2/2019 by 28 November 2023. The entire subscription price for subscriptions made with the stock options of EUR 6,050 will be entered in the Company's reserve for invested unrestricted equity.

After the trade registration the total amount of shares is 78,433,964.

The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about 20 December 2023, as of which date the new shares will establish shareholder rights.

The shares will be traded on the NASDAQ Helsinki Plc's First North Growth Market Finland marketplace together with the old shares on or about 21 December 2023.

For further information, please contact:

Peter Hänninen

General Counsel

peter.hanninen@nanoform.com

+358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.